















Governments worldwide are increasingly concerned about the booming use of CBD (cannabidiol) 
products. However, we know little about the impact of their liberalization. We study a unique case of 
unintended liberalization of a CBD-based product (light cannabis) that occurred in Italy in 2017. 
Using unique and high-frequency data on prescription drug sales and by exploiting the staggered local 
availability of the new product in each Italian province, we document a significant substitution effect 
between light cannabis and anxiolytics, sedatives, opioids, anti-depressants and anti-psychotics. 
Results are informative for regulators and suggest that bans on light cannabis use would disregard the 
needs of patients to seek effective reliefs of their symptoms. 
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The cannabis market has gained momentum worldwide. Ranging from recreational and medical 
marijuana to cannabis-derived products- such as CBD (cannabidiol), a relaxant compound of 
cannabis- its consumption is booming around the World. In Europe, marijuana is the most used illicit 
drug, with approximately 20% of individuals aged 15-24 having used it in 2018 (ECCMDA, 2019).1 
More recently, low-strength versions of cannabis such as hemp (or industrial hemp), rich in CBD, 
have also become widely popular and sold in the form of herbal cannabis (referred to as light cannabis, 
hereafter), lotions, extracts and candies. A major case of interest is Italy, a country with a conservative 
view on cannabis, but in which “light cannabis shops” unexpectedly blossomed due to a loophole in 
the legislation and received massive media and political attention.2 With the 2018 Farm Bill, hemp 
was removed from the definition of marijuana of the Controlled Substances Act and similar products 
have become available in the US as well, where this industry is expected to  be worth $20 billion by 
2024 (BDS Analytics).  
 
Despite the considerable interest that these products have received, little is known about the impact 
of this CBD market and several concerns have been raised regarding the health effects of their use. 
While, as pointed out by the National Academies of Sciences, Engineering, and Medicine (2017), 
CBD might not present itself as a risk for human health, this is certainly the case of its misuse to treat 
serious disorders. In May 2019, just before launching a public hearing with experts on CBD, the Food 
and Drug Administration (FDA) issued a warning that “misleading and false claims associated with 
CBD products may lead consumers to put off getting important medical care, such as proper 
diagnosis, treatment, and supportive care” (FDA, 2019).3 Likewise, due to high uncertainty, in 2019 
New York City banned CBD-derived food and drinks, whereas several states (i.e., Kansas, Indiana, 
Louisiana, Texas, and more recently North Carolina) announced or enforced a ban on light cannabis 
(New York Times, 2019). A similar hard stance on light cannabis was proposed by the Italian National 
Health Council (CSS) in 2018. The CSS expressed its concern about the safety of products based on 
cannabis inflorescence and suggested a ban on the commercialization of the product. In their 
 
1In the US, ten states and the District of Columbia allowed for recreational use of cannabis and many others approved medical marijuana 
laws.  As of 2018, Canada passed a law to remove restrictions on production, possession, and consumption of marijuana. In Europe, 
instead, most states have a strong stance against both versions of cannabis (ECCMDA, 2019).  
2In May 2019, the industry received massive media and political attention when the Italian Ministry of Interior, Matteo Salvini, started 
a crusade against local retailers. Local retailers were accused of being “places of mass miseducation” and helping the transition to real 
drugs (Reuters, 2019). 
3 In 2019, the US FDA issued FAQs regarding hemp and the recently approved the Farm Bill (2018). Responding to the question n. 4 
“Aside from Epidiolex, are there other CBD drug products that are FDA-approved? What about the products I’ve seen in stores or 
online?”, FDA stated that “We are aware that some firms are marketing CBD products to treat diseases or for other therapeutic uses, 
and we have issued several warning letters to such firms.” 
2 
 
statement, the CSS raised concerns about the impossibility of monitoring individual users, its effects 
in the short- and long-term, especially for some vulnerable consumers (e.g., minors, pregnant women, 
patients with other pathologies). 
 
This paper aims to reach a more in-depth understanding of the “hidden” use of light cannabis and 
attempts to investigate how people have reacted to the introduction of this new and potentially risky 
product in the market. On the one hand, as already pointed out by previous studies (e.g. Carrieri et al. 
2019), light cannabis can be a substitute for street marijuana and thus generate spillovers on the 
illegal market. On the other hand, for its relaxant effects, this product can be regarded as a substitute 
for existing drugs and induce self-medication. 
 
To explore this second channel, we exploit a unique case of unintended liberalization that occurred 
in Italy in 2017 when light cannabis was unexpectedly allowed to circulate in the market.4 Moreover, 
we use a unique dataset that combines the local availability of this light cannabis across Italian 
provinces and monthly sales of a large set of prescription drugs for which CBD is often advertised to 
be effective by producers. These include opioids, anxiolytics, sedatives, anti-migraines, anti-
epileptics, anti-psychotics and anti-depressants.  
 
Several features of the Italian case of liberalization make it an ideal setting to explore the causal 
substitution effect between light cannabis and prescription drug consumption. In December 2016, the 
Italian government passed a law (Law 242/16) to facilitate the cultivation of industrial hemp in Italy. 
Due to a loophole in the legislation, the law rendered “not illegal” the large-scale commercialization 
of the cannabis flower (light cannabis) in the absence of psychotropic effects (0.2-0.6% THC). Given 
the unintended scope of the liberalization, the product was sold as a collector’s item and not as a 
product suitable for human consumption, since May 2017. Critically, due to a lack of anticipation 
effects, this policy shock provides a plausibly exogenous variation in the policy setting. Indeed, this 
allows us to test the substitution between existing drugs and light cannabis in the absence of 
institutional adaptation and potential confounding factors (such as changes in national or local health 
policies). 
 
A second critical aspect is that the liberalization was accompanied by territorial heterogeneity in the 
market availability of the product. The presence of light cannabis shops was primarily driven by the 
 
4Another interesting case, which dealt with indoor prostitution, is provided by Cunningham and Shah (2018). The authors study the 
effects of a Rhode Island District Court ruling, which unexpectedly decriminalized indoor prostitution, on several outcomes such as 
sexual infections and violence, amongst others. 
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morphological and geographical conditions of the territory that made the cultivation of cannabis crops 
more suitable (see e.g., Carrieri et al., 2019). The first retailers of light cannabis were the already 
existing grow shops that, before the law was enacted, were selling products related to the cultivation 
of industrial hemp and, after the change in the legislation, began selling light cannabis exploiting 
large economies of scope. Subsequently, the commercialization of light cannabis flourished at a 
different pace across provinces. As the market availability of the product was not linked to the demand 
for illegal or medical marijuana as well as of pharmaceuticals, the market entry of these retailers can 
be regarded as plausibly exogenous in our setting.   
 
To identify the effect of interest, we exploit the idiosyncratic availability of light cannabis in the 
106 NUTS-3 Italian provinces in a staggered difference-in-differences (DiD) framework in the 
period of time surrounding the approval of the law. We find that the local availability of light 
cannabis led to a significant decrease in the number of dispensed boxes of anxiolytics by 
approximately 11.5%, a reduction of dispensed sedatives by 10% and a reduction of dispensed anti-
psychotics by 4.8%. More nuanced but still significant effects are found for anti-epileptics (-1.5%), 
anti-depressants (-1.2%), opioids (-1.2%), anti-migraines (-1%). An event study specification shows 
that the substitution between these pharmaceuticals had a larger effect starting from the third month 
after the introduction of the product in the local market and remains statistically significant also after 
six months post-liberalization. This is consistent with a learning process and the dynamics of self-
medication, which may stem from the need to be aware of the local market availability of the product, 
experimentation, and finally, more substantial partial or full self-medication. This interpretation is 
further corroborated by anecdotal evidence from Google Trends, which shows an increasing number 
of queries on the potential clinical effects of light cannabis after the policy. The figure indicates that 
patients might have searched for information regarding the new product and their potential relaxant 
effects when this became available.  
 
Finally, we find that drug prescriptions across provinces did not trend differently for up to six months 
prior to the light cannabis seller entry in the province, thus reinforcing our identification strategy. 
These results are robust in a number of checks, including alternative model specifications, 
randomization tests based on fake treatments and placebo regressions using drugs for which an a 
priori case of substitution with light cannabis cannot be made. In addition, we also perform a 
decomposition based on the recent contribution on difference-in-difference methods in the presence 
of a staggered rollout of the treatment, as provided by Goodman-Bacon (2018).  
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Our findings contribute to several streams of literature. Specifically, they relate to studies on the 
substitution effects induced by marijuana legalization. Dinardo and Lemieux (2001) and Crost and 
Guerrero (2012) used minimum drinking age regulations to show clear substitution patterns between 
alcohol and marijuana. Powell et al. (2018) show that medical marijuana laws, and in particular, the 
number of marijuana dispensaries, are associated with fewer opioid overdoses. Similar patterns were 
already documented by Shy (2017), Liang et al. (2018), Chan et al. (2020), Smith (2020) and 
McMicheal et al. (2020). Bradford and Bradford (2016; 2017; 2018) studied how the availability of 
medical marijuana impacted on Medicare and Medicaid drug prescriptions in the US, with a 
significant reduction for those related to pain relief, anxiety, nausea, depression, psychosis and sleep 
disorders.  
Our contribution to this stream of literature is threefold. First, this represents the first-ever evidence 
from Europe on the substitution effects induced by a compound of cannabis, the CBD. As the product 
is increasingly available in other European countries (e.g., Belgium, Germany), our results provide 
relevant implications for policymakers. Second, while there is a high degree of variation in medical 
and recreational marijuana laws in the US - where some states adopted a more liberal (almost 
recreational marijuana) approach, and others a stricter one (where people need a terminal diagnosis 
to get a prescription)- the Italian experience has been both liberal and strict at the same time. More 
importantly, the loophole in the legislation was homogenous in the entire country, although the local 
availability of the product was initially heterogeneous between local areas. Arguably, this represents 
a suitable setting to explore medical substitution between light cannabis and several different types 
of prescription drugs by exploiting territorial heterogeneity in product availability. Third, substitution 
effects arising from medical marijuana laws in the US require a doctor's prescription. Despite the fact 
that the physician’s involvement might be quite limited, i.e., because of their role as gatekeeper, this 
entails, in any case, a kind of supply-side driven substitution5. In our case, such a substitution is purely 
consumer-driven as it cannot involve the recommendation of a medical professional. This is because 
light cannabis is sold as a technical and collector’s item and, hence, virtually considered not suitable 
for human consumption. 
Moreover, our paper adds to the literature on the economics of these (potentially) risky behaviors (for 
a review, see e.g., Cawley and Ruhm, 2012). Traditionally, these behaviors, and in particular 
addictive ones (such as heavy drinking, smoking, and drug abuse), have mostly been considered as a 
 
5In the US, physicians in states where there is cannabis liberalization can sign a state form certifying that the patient has a qualifying 
medical condition to buy cannabis at dispensaries. However, their involvement in suggesting a cannabis-based therapy may be very 
limited and only related to their role as gatekeepers. 
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consequence of imperfectly rational individual’s choices, time-inconsistent preferences or triggered 
by incomplete information regarding possible risks.6 More recently, risky behaviors have been 
associated with the so-called “death of despair” (Case and Deaton, 2015). However, these may also 
emerge as a form of rational self-medication for symptoms not effectively treated by currently 
available drugs. This is the new perspective highlighted by Darden and Papageorge (2018), who 
recently proposed a novel rational interpretation that was consistent with a utility-maximizing 
framework and tested it empirically. They find that the availability of new and better drugs for 
depression has led to a reduction of forms of self-medication, such as alcohol, in the US. Our study 
contributes to this literature from a novel angle by testing the effect of the availability of a new product 
suitable for self-medication on existing drug consumption. The unintended nature of this 
liberalization offers the unique opportunity to test for the presence of self-medication by exploiting 
an exogenous variation in the availability of the product. 
Lastly, our analysis also complements the literature concerned with the effect of marijuana 
liberalization. This has already shown effects on other outcomes, e.g., crime (Carrieri et al., 2019; 
Chang and Jacobson, 2017; Gavrilova et al., 2017; Chu and Townsend, 2018; Dragone et al., 2019, 
inter-alia), traffic fatalities (Anderson et al., 2013; Hansen et al., 2020a), teenager use (Červený et 
al. 2017), fertility (Baggio et al., 2020), body weight and obesity (Sabia et al., 2017) but it lacks 
studies on drug consumption and self-medication.  
The paper is structured as follows: In Section 2, we present the policy reform that occurred in Italy. 
In Section 3, we discuss our data and the identification strategy. In Section 4, we present our main 
results, followed by some sensitivity analyses and robustness checks of these results in Section 5. In 
the final section, we present some concluding remarks. 
 
 
2 Institutional setting 
 
Italy has a long historical tradition of the cultivation of cannabis. One of the earliest large cannabis 
cultivations dates back to the 1st century A.D. (Mercuri et al., 2002). In the 1940s, Italy was the 
second-largest producer of industrial cannabis worldwide. Despite this fact, marijuana cultivation, 
possession, and sale remain illegal, except for its industrial and medical use. 
 
6 Starting with seminal contributions of Becker and Murphy (1988), the literature on rational addiction has been broadly tested on 
different outcomes, e.g., alcohol (Baltagi and Griffin, 2002; Dragone, 2009), cigarettes (Chaloupka, 1991; Becker et al.,1994), cocaine 




However, in 2016, the government passed Law 242/2016, which was intended to remove some 
restrictions on cultivation, transformation, and commercialization of industrial hemp, a strain of 
Cannabis sativa, widely used for textiles, clothing, and food. For its use, hemp is not classified as a 
drug as it is (almost) free of the psychoactive cannabis compound (THC). The latter should be kept 
below 0.6, and it is rich in CBD, a relaxant compound. Failing to account for this limit would imply 
narcotic effects and hence be subject to confiscation, closure, and risk of conviction for drug dealing. 
In 2018, as demand for CBD products grew, Italy had approximately 4,000 hectares of land dedicated 
to hemp cultivation, that is, ten times more than in 2013. 
 
The law, however, did not explicitly intervene on the commercialization of the cannabis flower, 
leaving a loophole in the legislation. As a result, as not explicitly forbidden, herbal cannabis was 
essentially liberalized. From May 2017 onwards, once the inflorescence phase was over, several 
startups exploited this grey and completely unregulated market and started selling light cannabis as a 
“technical product”, that is, as a collector’s item not meant to be smoked or consumed. The same 
retailers also started selling other CBD-based products such as oil, leaves, extracts, food and 
beverage. 
 
Interestingly, the local market availability of light cannabis did not arise simultaneously in all 
geographical areas of the national territory. Due to the unannounced liberalization, local availability 
in the first months after the policy mainly affected those areas previously served by grow shops, that 
is, shops selling seeds and cannabis-related products. As documented elsewhere (e.g., Carrieri et al., 
2019), these grow shops were mainly concentrated in those areas in which industrial cannabis 
cultivation was more likely due to the geographical and morphological conditions of the territory. As 
a result, the first retailers selling the product were those grow shops that, before the policy shock, 
were already supplying industrial hemp and items for its cultivation and that could exploit existing 
supply chains and networks. 
 
[Figure 1 around here] 
 
Figure 1 depicts this staggered entry into the market during the period covered by this study. In May 
2017, 22 out of 106 provinces were served by at least one light cannabis retailer. After a first 
introductory phase, light cannabis shops blossomed, thereby becoming a “social phenomenon”. 
Tobacco and herbalist shops, para-pharmacists and automatic machines began selling this product as 
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well and expanded their local coverage. As shown by Figure 1, by February 2018, the number of 
provinces reached 87 and the entire country was gradually covered by retailers throughout 2018. In 
2019, more than 1,000 shops were open. 
 
Interestingly, in May 2019, the situation in the market changed dramatically. The former Minister of 
the Interior, Matteo Salvini, announced a crackdown on this herbal cannabis sales and several retailers 
had their products confiscated as a precaution. The reason was that, in several cases, the flowers 
contained more THC than that allowed by the law to avoid being considered as an intoxicating 
substance. In turn, this triggered intervention from the police.7 In the same month, the Court of 
Cassation, Italy’s Supreme Court, aimed to close the loophole in the legislation by deciding to impose 
a ban on the sales of cannabis derivatives such as “oil, leaves, inflorescences, and resin”. However, 
the Court’s ruling left a backdoor open for a mild interpretation of the law for those CBD-derived 
products free of narcotic effects, creating more uncertainty in the market. Akin precautions, many 
companies and shops shut down in June 2019. This paper thus exploits this phenomenon during the 
period in which the market was entirely left unregulated. Figure 2 provides a time framework 
regarding our study, which covers market entry data from May 2017 to February 2018. 
 
[Figure 2 around here] 
 
 
3 Data and Methods 
 
We use a unique longitudinal dataset recording monthly drug sales and mapping the local market 
availability of retailers selling light cannabis at the province level (106 NUTS-3 provinces) over the 
period from January 2016 to February 2018.8 Data on these dispensaries were collected using the 
Archive Internet Wayback Machine on the websites of the four main producers of light cannabis in 
2017. These were then matched with data on prescription drug sales obtained by Federfarma, the 
Italian association of pharmacy owners. Our data tracks the pharmaceutical expenditure of the Italian 
 
7This was not the case of CBD, for which no limitation in its quantity per milligram existed. 
8We collected monthly information on the entry in a market in each Italian province by having access to archived copies of their early 
pages of the four main producers in 2017 (Easyjoint, Marymoonlight, RealHemp, XXXJoint) using the Internet Archive Wayback 
Machine https://archive.org/web/. Data were collected monthly from May 2017 (first entry in the market) and using the last accessible 




Local Health Authorities (ASLs) and covers more than 95% of Italian pharmacies. As one or more 
ASLs can serve a given province, data were aggregated at the province level (106 provinces). 
Our dataset tracks all “Class A” drugs dispensed by the Italian NHS containing active ingredients 
often used to treat symptoms for which marijuana can also provide relief or, at least, relaxant effects. 
Specifically, these refer to opioids, anxiolytics, hypnotics and sedatives, anti-migraines, anti-
epileptics, anti-psychotics and anti-depressives, as standardized for the ATC/DDD classification of 
the WHO Centre for Drug Statistics Methodology. This classification standardizes drugs based on 
the active principle and organs they treat (Anatomical Therapeutic Chemical Classification System 
ATC) and of the Defined Daily Dose (DDD). The latter accounts for “the average maintenance dose 
per day for a drug used for its main indication in adults”. 
 
Importantly, these drugs require a doctor’s prescription, which is typically provided in-person by the 
physician, and is available either free of charge or with a minimal patient co-payment.9 Moreover, 
there are two important caps which are designed to regulate individual drug consumption and make 
it strictly adherent to standardized therapies, as defined by the ATC/DDD system. First, there is a cap 
on the number of boxes that a doctor can prescribe, which is typically 2 for the drugs considered. 
Second, there is a cap on the length of the period a prescription can be refilled, which is typically 30 
days, and this ensures compliance with the dosing interval. In our framework, these caps allow us to 
measure the substitution effects in terms of DDDs for each ATC and, thus, rule out any intertemporal 
changes in the number of monthly packages sold. Finally, our dataset tracks all prescriptions that 
translated into a final sale in each province. 
 
The pharmaceuticals we consider have shown patterns of substitutability with medical marijuana 
(Bradford and Bradford 2016; 2017; 2018), which however presents some differences with respect 
to the light one. For instance, medical marijuana, rich in THC, is largely used to treat chronic pain, 
glaucoma, insomnia and anxiety. Instead, for its clinical effects, CBD is often associated with anti-
psychotic, analgesic, anti-inflammatory, anti-arthritic, and anti-neoplastic properties and is used to 
treat inflammations, migraines, depression, and anxiety (Blessing et al., 2015; CIBG, 2018). 
However, CBD-based products have come under scrutiny in the US for misleading claims made by 
some CBD producers relative to its effectiveness in treating the above pathologies. Apart from 
Epidiolex, a drug recently approved by the FDA to treat rare forms of epilepsy, no other drug 
 
9 According to Federfarma (2018), “Classe A “drugs are the most consumed drugs in Italy, accounting for approximately 52% of the 
entire market for pharmaceutical products (which also include dietary products, herbs, para-pharmaceuticals, and products for health 
and beauty care). Co-payments, which depends on the regional co-payment settings and individuals’ equivalent income, range from 1 
euro per box to 4 euro per the entire prescription. 
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contains CBD. Opioids were also included as, according to recent anecdotal evidence, Canadian 
veterans started substituting opioids (along with benzodiazepines) with marijuana after their 
introduction of medical marijuana in Canada to treat anxiety, insomnia and pain relief. Several 
scholars also documented similar patterns of substitutability with medical marijuana (e.g., Bradford 
and Bradford, 2016, 2018; Shi, 2017; Bachuuber et al., 2014). 
 
[Table 1 around here] 
 
Table 1 describes the main variables we use and shows a large heterogeneity across drug categories 
in the number of dispensed drug packets. On a monthly average, the Italian NHS provides 
reimbursement for 28 packets of sedatives and 72 boxes of anxiolytics per province. Much higher 
numbers are documented for anti-epileptics (18,460 packets), antipsychotics (4,802 packets) and anti-
migraines (2,504 boxes). With 27,198 packets sold on average, anti-depressants represent the drug 
with the largest sales in our sample. ISTAT, the Italian National Institute of Statistics, estimates that 
more than 2.4 million Italians suffered from mental health problems in 2015, and approximately 1.3 
million presented symptoms of depression (ISTAT, 2018). 
 
Interestingly, opioids, which are widely used in the US and Canada for acute and chronic pain relief 
but which have severe side effects such as dependency and sedation, show lower numbers, accounting 
for an average monthly sale at the province level of 12,610 packets. Although the number of 
prescriptions increased in recent years, these numbers depict the general level of skepticism among 
Italians concerning this drug. 
 
Finally, by matching this information with those available from light cannabis local retailers, we 
obtained a balanced panel with a total of 2,756 province-month observations. 
 
 
3.1 Identification Strategy 
In order to identify the causal effect of light cannabis on the prescriptions of drugs, we employ a 
staggered DiD, which exploits the idiosyncratic availability of light cannabis in a given province.10 
 
10 In text context of substances, a similar identification strategy based on a staggered rollout of the opium policy in the Java during the 
period 1875–1904 was provided by van Luijk and van Ours (2001). Similarly, Dragone et al. (2018) exploit the staggered adoption of 
the recreational marijuana laws in the states of Washington and Oregon to study its effects on crime. 
10 
 
Thus, our identification relies both on the staggered timing of the product availability and the 
provinces without any retailer as the control group.11 More formally, we estimate the following 
equation: 
𝑌!" = 	𝛼 +&𝛽#
#
𝐸𝑛𝑡𝑟𝑦!# + 𝛿𝑋!" + 𝛾! + 𝜇" + 	𝜀!" 
where 𝑌it is the number of packets of dispensed drugs (i.e., opioids, anxiolytics, sedatives, anti-
migraines, anti-epileptics, anti-depressants and anti-psychotics) reimbursed by NHS at the time 𝑡 in 
the province 𝑖, Entry is an indicator that takes value 1 if at least a cannabis retailer has entered in all 
periods k<t in province i. 𝛾 and 𝜇 are province and time (month and year) fixed effects, 𝜀 represents 
the error term. Xit is a vector of controls for province population size and density and a dummy for 
the post-May period to take into account eventual changes that occurred at the national level after the 
unintended liberalization. Our coefficient of interest is 𝛽, which captures the monthly change in the 
sales of dispensed drugs due to the local availability of light cannabis. 
 
The credibility of our identification strategy relies on the natural experiment which characterized the 
policy. As discussed, the policy was unannounced and concerned hemp, a product that, when sold as 
light herbal cannabis, differs in its composition from both recreational and medical marijuana. Thus, 
the entry of light cannabis retailers in a local market can be regarded as plausibly exogenous as it was 
not linked to the demand for illegal or medical marijuana as well as pharmaceuticals. Moreover, the 
possibility of endogenous entry is essentially ruled out for several reasons. First, the precise nature of 
the unintended liberalization process rendered any anticipatory effect to be implausible. The law was 
approved in December 2016 and, after an early cultivation phase, the product was first marketed in 
May 2017. Second, the local availability during the period under investigation mainly depended on 
the geographical presence of grow-shops before the policy change. The latter are retailers specialized 
in industrial hemp, which were the first to sell light cannabis after the liberalization by exploiting 
large economies of scope and their existing supply chains (see, for example, Carrieri et al., 2019). 
Finally, we make use of high-frequency data to focus on a narrow time window surrounding the 
implementation of the (unintended) policy (May 2017 – February 2018). This allows us to rule out 
potential changes in national and local health policies concerning prescribed drugs and systematic 
 
11In our identification strategy, we cannot rule out cross-province movements to buy light cannabis, as recently shown by Hansen et 
al. (2020b). However, in the period we consider, it is implausible that people managed to know about the local availability of light 
cannabis in a different province and systematically move to that province accordingly to buy the product. As a result, in our setting, 




changes in the prescription choices of medical doctors. This is because any change requires time to 
be fully operational and extensively included in medical guidelines and protocols.  
More formally, our empirical analysis relies on the classical DiD’s identifying assumptions in the 
pre-liberalization periods, that is, the existence of a common trend in drug prescriptions. In our 
setting, it implies assuming that those provinces experiencing different timings in the local 
availability of light cannabis (treatment group) and those provinces never served by cannabis retailers 
in the period we consider (control group) should have observed the same pre-policy trends for all 
drug categories. In Section 5, we find strong support for this hypothesis by performing a visual 
inspection of common trends and more formal tests such as placebo regressions and falsification tests 




Our results are reported in Table 2 for all pharmaceuticals for which medical marijuana can be 
considered as a substitute or adjuvant therapy. For ease of interpretation, the dependent variable is 
expressed in logs. This allows us to interpret the DID-coefficient as the average percentage change 
in the monthly number of dispensed drugs resulting from the local availability of light cannabis. 
 
[Table 2 around here] 
 
For all drug categories, we document a significant and negative effect. Specifically, as the market 
availability of light cannabis became possible due to the entry of at least one retailer in a given 
province, the number of dispensed drug sales fell by approximately 1.6%, on average. The extent of 
this reduction reveals a considerable degree of heterogeneity. The boxes of anxiolytics prescribed by 
doctors and sold by pharmacies significantly decreased by 11.4%, the sedatives consumption 
decreased by approximately 10%, while the number of anti-psychotics decreased by 4.8%. These 
drugs account for the most considerable reductions. Interestingly, these are also the type of drugs for 
which CBD – but not light cannabis itself - is recognized or advertised as having a clinical effect, 
that is, to treat anxiety and psychosis (Blessing et al. 2015; CIBG, 2018). This is intuitively explained 
by the relaxant properties of CBD, which is often used to treat sleep disorders. Moreover, the large 
coefficients that we observe for sedatives and anxiolytics can be explained by the marketing 
strategies for cannabis and CBD-related products sold, which are typically advertised for its 
relaxant effects. These marketing strategies fueled a government investigation in the US. This result 
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may suggest that patients decided to (partially) abandon a conventional medical treatment and 
switched to light cannabis to treat symptoms such as anxiety and sleep disorders.  
More relatively nuanced yet, significant reductions are found for other pharmaceuticals, which appear 
to offer a more chronic therapy. These findings are consistent with a self-medication interpretation 
also for these drugs. There is a mild average monthly reduction in the number of packets for anti-
epileptics (-1.5%), anti-depressants (-1.2%), opioids (-1.2%) and anti-migraines (approximately -
1%). These are all drugs requiring a constant and consistent therapy, often prescribed by specialists, 
and for which the switching to an “alternative therapy” based on self-medication may be more 
problematic, especially for risk-averse individuals. Still, despite the short time window, local market 
availability of light cannabis and other cannabis-derived products led to a reduction in prescription 
drugs but with a lower intensity. 
 
Moreover, it is noteworthy that opioids, anti-depressants and anti-epileptics are all pharmaceuticals 
that show severe side effects and can be associated with a social stigma. In Italy, opioids are also 
generally less prescribed than in the US, where unregulated prescription led to an opioid crisis (Case 
and Deaton, 2015). Indeed, some patients may have seen in this new product the possibility to seek 
(partial) relief or improve their quality of life, for instance, by making use of a mostly accessible 
product which does not require any medical prescriptions and which is perceived to be of regular use 
(e.g., oils, essences, or even similar to recreational yet illegal cannabis).  
 
An interpretation consistent with the self-medication hypothesis is also anecdotally supported by 
looking at online information seeking. Figure 3 provides further support for the use of light cannabis 
as a form of self-medication using Google Trends statistics. It shows that both the general interest in 
the product and its use to treat anxiety disorders peaked in the month of the introduction of the product 
into the Italian market (May 2017) and remained at a higher level in the subsequent period. This 
supports the idea that people were seeking information online for treating their symptoms before 
actually switching to the new product. 
 
[Figure 3 around here] 
 
One can note that our results share some similarities with those found by Bradford and Bradford 
(2016; 2017). However, there are relevant differences. They showed a larger reduction in drug 
prescriptions (up to 10-20%) than ours. These differences can be attributed to a number of causes. 
First, they focus on some population samples restricted to those eligible for either Medicare Part D 
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or Medicaid, whereas our data refers to the overall number of drug sales (and indeed) prescriptions 
without age limitation and eligibility constraints. Hence, our results may indicate that substitution 
effects are lower when estimated on a general population. Second, we focus on a non-medical 
treatment (i.e. light cannabis) that can be bought without a physician’s indication. Indeed, we estimate 
a demand-driven substitution. With these lenses, our results suggest that a substitution driven by self-
medication may be lower than the one also induced by the physician.  
 
 
5 Robustness Checks 
 
To assess the robustness of our results, we present results of several checks. First, we restrict the time 
before the policy. This renders the time windows more symmetrical before and after the policy (May 
2016 - February 2018). Despite reducing the number of observations (2,332), our main results and 
intuitions remain unaltered. Estimates of the DID coefficients are reported in the first row of Table 3 
for all drug categories we consider. Specifically, the local availability of light cannabis leads to a 
reduction in the number of dispensed boxes of sedatives by 11.5%, anxiolytics by 12.3% and anti-
psychotics by 4.3%. Consistently with the baseline specification, we find a more subtle but significant 
effects on other prescribed drugs: the selling of anti-epileptics decreases by 1.5%, whereas those of 
anti-depressants, opioids, and anti-migraines decrease by approximately 1%. 
 
Second, we include a linear time trend to capture any time-varying confounding factor which might 
affect our estimates. Estimates of the DID coefficient are reported in the second row of Table 3 and 
are very similar to those reported in the main model specification. Moreover, we include province-
specific time trends. This allows us to allay any remaining concerns regarding province-specific 
changes in prescriptions and drugs sale. Results are reported in the last row of Table 3 and are 
qualitatively similar to those presented in Table 2. However, we observe a reduction in the coefficient 
of anti-psychotics, which loses significance but remains negative. We thus suggest a more cautious 
interpretation of this effect. 
[Table 3 around here] 
 
Third, we test whether the common trend assumption can be credibly maintained. A typical concern 
which may arise when adopting a DID approach is the presence of pre-policy trends, which may drive 
the main results. To allay this concern, we make a visual inspection of the trends for provinces 
experiencing early (May – September 2017) and late (October 2017 – February 2018) local 
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availability in the market and for those provinces never exposed to access to light cannabis during the 
period we consider. This allows us to verify whether provinces experiencing different timings in the 
entry of light cannabis retailers followed similar trends in drug sales before the actual liberalization 
(May 2017). As highlighted in Figure 4, pre-policy trends are parallel and the post-policy drop in 
dispensed drugs is consistent with the timing of the local availability in treated provinces, compared 
to the controls. This supports the credibility of the common trend hypothesis in our setting. 
 
[Figure 4 around here] 
 
Fourth, we perform a placebo test using as dependent variables prescription drugs for which there is 
no medical evidence of possible substitution patterns with light cannabis. Indeed, we consider insulin, 
anti-hypertensives and genito-urinary system drugs (sex hormones and urological), which do not 
belong to the category “N – Nervous System” of the WHO Collaborating Centre for Drug Statistics 
Methodology. For these drugs, we use the ATC/DDD classification which standardizes the average 
drug doses for adults. As treating other pathologies, these prescription drugs should not be affected 
at all by the light cannabis availability. Estimates are reported in Table 4. All the DID coefficients 
are not statistically significant and very close to zero in magnitude. This provides further support to 
our main results in terms of causality.  
 
[Table 4 around here] 
 
To reduce any residual concern about possible violations of common trend assumptions, we also 
perform a permutation test based on a Monte Carlo simulation. The permutation test also allows us 
to explore the robustness of the results to assumptions about the structure of the error distribution. 
This is a strategy used in many empirical applications (e.g., Wing and Marier, 2014). Hence, we 
simulate the effect of local accessibility to light cannabis by randomly assigning the treatment to 
provinces at different points in time, in place of the real one. We repeat this procedure 5,000 times to 
generate a distribution of placebo treatment effects. Figure 5 presents the non-parametric distributions 
of these placebo estimates for all prescribed drugs included in our study, separately.  
 
[Figure 5 around here] 
 
Figure 5 shows that the average of the placebo treatments is zero and the actual coefficient, which is 
depicted by the red vertical line, falls far from the left tail of the distribution. As a result, this indicates 
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that the negative and significant effect we find on drug prescriptions is very implausible to have 
occurred by chance. 
 
Finally, to account for the recent developments in the econometric literature in the presence of a 
staggered rollout of the treatment (e.g., Athey and Imbens, 2018; Goodman-Bacon, 2018), we study 
the time-varying nature of the policy and the weights associated with its component. Following 
Goodman-Bacon (2018), we plot all the 2X2 pairwise DID estimates (on the vertical axis) against 
their weights (on the horizontal axis). Figure 6 indicates that the opening of a light cannabis shop led 
to a reduction in the sales of prescription drugs. The red line represents the weighted DID coefficient 
once accounting for the different weights associated to its component. Notably, the coefficients are 
all negative and qualitatively similar to our benchmark results.12 
 
[Figure 6 around here] 
 
One can note the following two results. First, treated vs. never treated are the ones with the largest 
weight. For instance, the weight associated with this group is always 52%. This suggests that the 
latter is the main source of identification in our setting. Second, we note that while some 2X2 pairwise 
comparisons are positive, their weight is very close to zero. Thus, the average weighted DID 
coefficient is always negative for all our outcomes and, in some cases, this is even relatively larger. 
For example, in the case of sedatives, the average coefficient indicates a reduction in sales of-0.16 (-
0.095 in our baseline DiD). In the case of anxiolytics, the average coefficient is -0.22 (-0.114 in the 
baseline DiD). However, we take a conservative stance, interpreting the results from our main DID 
as a lower bound estimate. 
 
 
5.1 Event Study 
 
To shed some further light on the observed substitution, we also explore the dynamic of patients’ 
responses to local market availability of the new cannabis-light product. By exploiting a rather rare 
policy set-up with heterogeneous and staggering effects at a local level, our setting is ideal for 
studying patients’ responses and for verifying the self-medication hypothesis discussed above. We 
 
12 Estimates shown in Figure 6 are based on a seasonally-adjusted outcome variable in order to take into account the seasonal pattern 
in drug prescription. The original DiD accounts for the presence of month dummies, which are not implementable yet using the 
decomposition routines available in statistical software. Consequently, while the main sources of heterogeneity in the estimates can be 
assessed, point estimates are not directly comparable 
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thus perform an event study analysis conceived as follows. We include in equation (1) a series of 
dummies coding the month in which entry in the market occurred and one to six months pre-entry 
and post-entry. One-month pre-entry is the excluded dummy for each dimension and is set equal to 
zero in our presentation of the results.  
 
Results of the event study specification are reported graphically in Figure 7. We find that reductions 
in the number of dispensed drugs occur since the second month after the entry of local retailers and 
it is more pronounced from the third month onwards. The figure also shows non-linearity in the 
substitution pattern but proves to be a statistically significant effect also in the six months following 
the local product availability. Importantly, Figure 7 also shows that there is little evidence of 
systematic pre-trends affecting the results and this provides further support for the hypothesis of 
exogeneity in the cannabis light seller entry in each province. Lastly, looking at the magnitude of 
these effects, we find an average post-treatment coefficient of -0.015. This is very close to our main 
DiD specification (column 1, Table 2). This suggests once again that timing heterogeneity is not 
driving our main results. 
 




Many countries worldwide have legalized or decriminalized marijuana for recreational and medical 
purposes. Others have recently legalized the cultivation for commercialization of hemp, an industrial 
strain of cannabis rich in CBD and almost free of psychoactive components. While on the one hand, 
this market is gaining momentum and is often described as the new “green oil”, on the other hand, 
uncertainty is increasing among regulators and authorities about potential misuse. Given the 
uncertainty on how to govern this phenomenon and exploiting the difficulties in distinguishing light 
cannabis from illegal marijuana, several states such as Kansas, Louisiana, Texas and North Carolina 
opted for a tough stance by banning smokable hemp. Yet, this mostly unregulated market kept 
booming. 
 
This paper provides a self-medication argument for such popularity by exploiting a unique 
opportunity offered by a loophole in the Italian legislation regarding the commercialization of a new 
CBD-based product. Indeed, we look at whether the availability of a new product suitable for self-
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medication impacted on dispensed drug sales to treat anxiety, psychosis, chronic pain, insomnia, 
migraine and epilepsy. 
 
Using a staggered DiD model and considering monthly data for 106 Italian provinces during the 
period between January 2016 and February 2018, we find that the local availability of light cannabis 
led to a significant and large reductions of dispensed boxes of anxiolytics and sedatives, which 
amounted to approximately 10%. These drugs usually treat symptoms for which CBD is often 
effective and for which a non-specialist can easily detect symptoms. We also find that the entry of a 
light cannabis retailer in a given province led a 1-1.5% reduction in the number of anti-epileptic, anti-
depressant, opioid and anti-migraine prescriptions. In contrast, prescriptions for psychotic patients 
decreased by approximately 4-5%. Much higher coefficients are more likely to emerge when 
considering a more extended time window. Indeed, our coefficient indicates a lower bound for the 
effect of light cannabis on prescription drugs. In contrast, no substitution effect was found for 
prescription drugs without relaxant effects, such as insulin, hypertensives, as well as sex hormones 
and urological. 
 
Our results are compatible with a self-medication hypothesis, that is, the adoption of risky behaviors 
to seek a quality of life improvements and relief. Indeed, the large-scale accessibility to the new 
product, which was advertised as a relaxant one, induced some patients to abandon traditional 
medicine to seek relief. Self-medication arises as the product was neither suitable for medical 
purposes nor was allowed to be consumed. This renders less likely that the substitutional patterns we 
observed were driven by medical advice. As discussed, light cannabis liberalization was due to a 
legislative void and, for this reason, unannounced and not capable of creating an anticipatory effect, 
therefore reducing the likelihood of “off the record” medical advice. Our estimates assume more 
relevance when considering the relatively short time window we consider, that is 10 months after 
the policy was implemented, the lack of clinical support, and the unusual way in which light 
cannabis was made available as well as our focus on a short period after the introduction of the 
product. Patient response to new drugs and therapies is usually heterogeneous and sluggish because 
of typical risk aversion. Nonetheless, we find a significant and negative effect on several drugs 
treating pathologies for which medical cannabis (and not light cannabis) has demonstrated some 
degree of effectiveness.  
 
The event study also provides additional insights into patients’ responses. We observe that 
substitutional patterns are more accentuated starting from the third month after the entry of the first 
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light cannabis retailer in the local area and significant also after six months post entry. This result 
may indicate that individuals started substituting therapy after some weeks of experimentation or just 
after realizing that the new product had become locally available, thereby reinforcing the “rational” 
characterization of self-medication. In this sense, the paper provides a self-medication explanation, 
different from “hype-seeking” for the explosive success of cannabis-derived products, even in the 
absence of the psychoactive compound (THC), in the US and Europe. 
 
Finally, our estimates present a series of important public policy implications that go beyond Italy’s 
case. First, the substitution we identify may stem from the patients’ needs of more effective relief, 
which is not currently addressed by traditional medicine. This configures a form of market failure 
that lawmakers should account for. One way could be to improve the current distribution channel of 
medical marijuana. Absent any further policy change in this direction, our study suggests that policies 
such as a ban on light cannabis, as promoted by several US states and by Italian policymakers in 
2019, might eventually decrease patients’ welfare as disregarding their needs for more effective relief. 
 
Second, forms of self-medication may, at first, ring the alarm bells of policymakers as individuals 
may not follow expert advice even when taking care of their health. Our results suggest that regulatory 
authorities should be cautious and vigilant as the large-scale availability of light cannabis may induce 
substitution patterns not clinically validated. Moreover, our study highlights that regulation of light 
cannabis is required. In a similar vein, a more general public health campaign should complement 
such a policy. For instance, instructing doctors and providing labels and certification alongside 
information regarding doses for these products may be a first attempt to make light cannabis, and in 
general CBD-derived product consumption, much more controlled. 
 
Third, from a public policy perspective, we observe that the shift in consumption from traditional 
drugs to light cannabis came from a non-negligible cost for a patient. This is because, unlike the drugs 
we consider, which are either fully reimbursed by the Italian NHS or subject to a small co-payment 
from a patient, light cannabis is often sold at 8-10 euros per gram. This suggests that the unintended 
policy liberalization led to an unexpected contraction of pharmaceutical expenditure, ceteris paribus. 
As pharmaceutical expenditure worldwide has rapidly increased in recent years and this is equally 
true in Italy (Federfarma, 2018), the presence of such short-term financial benefits should be 
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Figures and Tables 
 
Figure 1. Timing of Local Availability of Light Cannabis 
 
 
The map reports the different timing of local availability of light cannabis in the 106 provinces we consider starting from May 2017. 





Figure 2. Timeline 
 
Our study covers monthly data from January 2016 to February 2018. The Law (242/2016) was approved on December 2016. In May 
2017, the first entry in the market occurred (see Figure 2). In May 2019, Italy’s High Court decided about the possibility to 








































Figure 3. Google Trends Queries on “cannabis light” and “cannabis light + anxiolytics” in 
Italy  
 
The figure presents the number of Google Search queries on “cannabis light” and “cannabis light + ansiolitico (anxiolytics)” in Italy 
during the period we considered. In May 2017, when the product was announced, the number of queries had a spike and the number 















Figure 4. Common Trend 
 
The figure presents the trends in all dispensed drugs in our dataset (opioids, anxiolytics, sedatives, anti-migraines, anti-epileptics, anti-
psychotics and anti-depressives) for provinces exposed to early, late and no local accessibility to light cannabis. Early entry refers to 
local availability during the first 5 months after the first entry (between May and September 2017). Late entry refers to local availability 
during the last 5 months we observe, which is between October 2017 and February 2018.  
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Figure 5. Randomization Inference 
 
 
The figures show the distributions of the placebo estimates based on 5,000 permutations for all out outcomes separately. The vertical 




Figure 6. 2x2 DiD Estimates (Goodman-Bacon Decomposition) 
 
 
The figure plots each 2 × 2 DiD estimate against their weights calculated following the Goodman-Bacon (2018)’s decomposition for 
all prescription drugs considered in our model. The triangle refers to estimates where one timing group acts as treatment group and the 
never treated country as control group. The grey x’s refer to timing-only estimates in which the early treated group acts as treatment 
group and the later treated group as control group. The black x’s refer to timing-only estimates in which the later treated group acts as 
treatment group and the earlier treated group as control group. The red horizontal line refers to the weighted average DiD coefficient 





Figure 7. Event Study 
 
 
The figure presents an event study of the effects of local availability (represented by the red vertical line) on all dispensed drugs. One-




Table 1. Descriptive Statistics 
 
Variable ATC/DDD Description Mean Std. Dev. 
     
Sedatives N05C Monthly number of dispensed sedatives and hypnotic drugs per province (boxes) 28.20 109.73 
Anxiolytics N05B Monthly number of dispensed anxiolytics per province (boxes) 72.52 359.45 
Anti-epileptics N05A Monthly number of dispensed anti-epileptics per province (boxes) 18,459.67 21,474.39 
Opioids N02A Monthly number of dispensed opioids per province (boxes) 12,610.91 13,065.20 
Anti-migraines N02C Monthly number of dispensed anti-migraines per province (boxes) 2,504.26 2,626.09 
Anti-psychotics N05A Monthly number of dispensed anti-psychotics per province (boxes) 4,802.44 5,903.55 
Anti-depressives N06C Monthly number of dispensed anti-depressives per province (boxes) 27,198.25 26,290.68 
     
Nr. Observations   106 provinces X 26 months 2,756  
Note: data are made available by Federfarma for all “Classe A” drugs dispensed by the Italian NHS. Sales are registered based on the 
WHO ATC/DDD, which classifies drugs based on a technical unit of measurement called the Defined Daily Dose (DDD).   
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Table 2. Difference-in-Differences regression 
 
 (1) (2) (3) (4) (5) (6) (7) (8) 






         
DiD -0.016*** -0.095* -0.114** -0.015*** -0.012** -0.009* -0.048** -0.012*** 
 0.004 0.053 0.055 0.004 0.005 0.005 0.018 0.003 
         
Controls yes yes yes yes yes yes yes yes 
Year FE yes yes yes yes yes yes yes yes 
Month FE yes yes yes yes yes yes yes yes 
Province FE yes yes yes yes yes yes yes yes 
         
N 2,756 2,756 2,756 2,756 2,756 2,756 2,756 2,756 
 
Log-transformation of the dependent variable. S.E. clustered at the province-level in italics. ***, **, * indicate statistical significance 


















Table 3. Robustness checks: parameter estimates 
 
 (1) (2) (3) (4) (5) (6) (7) (8) 






         
Shorter time -0.016*** -0.115** -0.123** -0.015*** -0.011** -0.010** -0.043** -0.012*** 
window 0.003 0.054 0.058 0.004 0.004 0.005 0.018 0.003 
         
Linear trend -0.016*** -0.100* -0.115** -0.014*** -0.011** -0.010* -0.047** -0.012*** 
 0.004 0.052 0.055 0.004 0.005 0.005 0.018 0.003 
         
Province-trend -0.017*** -0.186** -0.157* -0.018*** -0.019*** -0.012** -0.020 -0.011*** 
 0.003 0.076 0.093 0.003 0.004 0.005 0.013 0.003 
         
Log-transformation of the dependent variable. S.E. clustered at the province-level in italics. ***, **, * indicate statistical significance 
at 1%, 5% and 10%, respectively. The first row reports the estimates of the DID coefficient considering a shorter time window (May 
2016 – February 2018). The second row reports the estimates of the DID coefficient in the presence of a linear trend. The third row 






































Table 4. Robustness checks: placebo regressions 
 
 (1) (2) (3) 
 Insulin Anti-hypertensives Sex Hormones and 
Urologicals 
    
DiD 0.015 -0.002 0.006 
 0.034 0.005 0.006 
    
Controls yes yes yes 
Year FE yes yes yes 
Month FE yes yes yes 
Province FE yes yes yes 
    
N 2,756 2,756 2,756 
The drugs considered refer to the following ATC/DDD classification of the WHO Collaborating Centre for Drug Statistics 
Methodology: A10A (Insulin), C02 (Anti-hypertensive), G03 and G04 (Sex hormones, modulators of the genital system and 
Urologicals). Log transformation of the dependent variable. S.E. clustered at the province-level in italics. 
 
